Last reviewed · How we verify
NCT05732337
Open Clinical Investigation to Evaluate the Effectiveness and Safety of a Topical Medical Device.
NA trial testing Poxclin Coolmousse in Chickenpox in 28 participants. Completed in 5 July 2023.
5 July 2023
Quick facts
| Lead sponsor | Karo Pharma AB |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 28 |
| Start date | 30 January 2023 |
| Primary completion | 5 July 2023 |
| Estimated completion | 5 July 2023 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- Poxclin Coolmousse
Conditions studied
- Chickenpox — all drugs for Chickenpox →
Sponsor
Karo Pharma AB
Who can join
Adults 12 Months to 11, any sex, with Chickenpox. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary endpoint is the change of the itching score after 3 days of the product use in comparison to the basal value.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05732337
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chickenpox
Currently open trials in the same condition.
- NCT06806137 — A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Heal · Phase 3 · recruiting
- NCT06855160 — A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rub · Phase 3 · recruiting
- NCT06740630 — A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to · Phase 3 · recruiting
- NCT06693895 — A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age · Phase 3 · recruiting
Other Karo Pharma AB trials
Trials by the same sponsor.
- NCT07233473 — Evaluation of the Effectiveness and Safety of a Vaginal Gel for Prevention of Recurrent Urinary Tract Infections · NA · recruiting
- NCT07234786 — Clinical Study of a Vaginal Gel for the Treatment and Prevention of Vaginal Infections · NA · recruiting
- NCT05552378 — Multi-Gyn FloraFem Study for Treatment of Vulvo Vaginal Candidiasis Symptoms · NA · completed
- NCT05560841 — Effectiveness and Safety of Nailner Brush 2in1 in Onychomycosis · NA · completed
- NCT05211921 — Single Arm Study of Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05732337 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Karo Pharma AB
- Last refreshed: 8 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05732337.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing